Page last updated: 2024-12-06

4-acetylaminofluorene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-acetylaminofluorene : A member of the class of acetamides that is acetamide in which one of the hydrogens attached to the nitrogen is replaced by a 9H-fluoren-4-yl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID34210
CHEMBL ID2311070
CHEBI ID76343
SCHEMBL ID1273609
MeSH IDM0092047

Synonyms (37)

Synonym
n-9h-fluoren-4-ylacetamide
4-acetylaminofluorene
acetamide, n-9h-fluoren-4-yl-
n-4-fluorenylacetamide
28322-02-3
acetamide, n-fluoren-4-yl-
nsc9866
nsc-9866
nsc 9866
brn 2975269
acetamide, n-9h-fluoren-4-yl
acetamide, n-fluoren-4-yl
einecs 248-964-3
hsdb 4329
4-acetylaminofluoren [german]
ccris 735
4-acetamidofluorene
4-fluorenylacetamide
n-fluoren-4-ylacetamide
4-aaf
n-(9h-fluoren-4-yl)acetamide
n-(9h-fluoren-4-yl)ethanamide
A819413
unii-u41bo8xu2z
u41bo8xu2z ,
4-acetylaminofluoren
FT-0617383
AKOS015889873
4-acetylaminofluorene [hsdb]
chebi:76343 ,
CHEMBL2311070
4aaf
SCHEMBL1273609
PHPWISAFHNEMSR-UHFFFAOYSA-N
DTXSID1020019
n-(9h-fluoren-4-yl)acetamide, aldrichcpr
Q27145900

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" dosing with 100 mg/kg CPA once a week for 6 successive weeks induced, as compared to controls, a significant increase in the number and area of gamma-glutamyltranspeptidase-positive foci."( Induction of micronuclei and initiation of enzyme-altered foci in the liver of female rats treated with cyproterone acetate, chlormadinone acetate, or megestrol acetate.
Allavena, A; Brambilla Campart, G; Brambilla, G; Ghia, M; Martelli, A; Mereto, E, 1996
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
mitogenA chemical substance that encourages a cell to commence cell division, triggering mitosis.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
acetamidesCompounds with the general formula RNHC(=O)CH3.
fluorenesAn ortho-fused polycyclic arene in which the skeleton is composed of two benzene rings ortho-fused to cyclopentane.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (25)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (36.00)18.7374
1990's16 (64.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.25 (24.57)
Research Supply Index3.33 (2.92)
Research Growth Index4.58 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.70%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (96.30%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]